loading
Acadia Pharmaceuticals Inc stock is traded at $14.27, with a volume of 1.04M. It is down -0.70% in the last 24 hours and down -14.95% over the past month. Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
See More
Previous Close:
$14.38
Open:
$14.6
24h Volume:
1.04M
Relative Volume:
0.65
Market Cap:
$2.50B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
79.25
EPS:
0.18
Net Cash Flow:
$80.53M
1W Performance:
-4.74%
1M Performance:
-14.95%
6M Performance:
-1.65%
1Y Performance:
-15.95%
1-Day Range:
Value
$14.08
$14.81
1-Week Range:
Value
$14.08
$14.88
52-Week Range:
Value
$13.40
$20.68

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
Name
Acadia Pharmaceuticals Inc
Name
Phone
858-558-2871
Name
Address
12830 EL CAMINO REAL, SAN DIEGO
Name
Employee
654
Name
Twitter
@acadiapharma
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
ACAD's Discussions on Twitter

Compare ACAD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ACAD
Acadia Pharmaceuticals Inc
14.27 2.50B 890.53M 30.57M 80.53M 0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
489.15 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
583.23 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.94 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.89 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.05 26.16B 3.81B -644.79M -669.77M -6.24

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-11-25 Initiated Deutsche Bank Hold
Jan-03-25 Downgrade Guggenheim Buy → Neutral
Oct-10-24 Resumed Raymond James Mkt Perform
Aug-07-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-27-24 Initiated BMO Capital Markets Outperform
Mar-12-24 Downgrade Mizuho Buy → Neutral
Mar-12-24 Reiterated Needham Buy
Jan-30-24 Initiated Robert W. Baird Outperform
Jan-24-24 Upgrade Needham Hold → Buy
Dec-19-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-14-23 Downgrade Deutsche Bank Buy → Hold
Dec-13-23 Initiated Citigroup Buy
Dec-12-23 Initiated Deutsche Bank Buy
Nov-06-23 Upgrade Mizuho Neutral → Buy
Oct-17-23 Initiated UBS Buy
Oct-10-23 Upgrade JP Morgan Neutral → Overweight
Jan-03-23 Upgrade Guggenheim Neutral → Buy
Nov-04-22 Downgrade Goldman Neutral → Sell
Nov-01-22 Initiated Loop Capital Hold
Aug-08-22 Downgrade Citigroup Buy → Neutral
Aug-05-22 Downgrade Citigroup Buy → Neutral
Jun-21-22 Downgrade Jefferies Buy → Underperform
Jun-16-22 Upgrade Jefferies Hold → Buy
Mar-16-22 Upgrade Canaccord Genuity Hold → Buy
Feb-09-22 Upgrade H.C. Wainwright Neutral → Buy
Jan-05-22 Upgrade Citigroup Neutral → Buy
Dec-21-21 Downgrade Guggenheim Buy → Neutral
Nov-01-21 Upgrade Guggenheim Neutral → Buy
Oct-14-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-21 Resumed Needham Hold
Jun-10-21 Initiated Berenberg Hold
Apr-07-21 Downgrade H.C. Wainwright Buy → Neutral
Apr-06-21 Downgrade Canaccord Genuity Buy → Hold
Apr-06-21 Downgrade Goldman Buy → Neutral
Apr-06-21 Downgrade Jefferies Buy → Hold
Apr-06-21 Downgrade Mizuho Buy → Neutral
Apr-05-21 Downgrade Raymond James Outperform → Mkt Perform
Mar-10-21 Downgrade BofA Securities Buy → Neutral
Mar-09-21 Downgrade Citigroup Buy → Neutral
Mar-09-21 Downgrade Guggenheim Buy → Neutral
Mar-09-21 Reiterated H.C. Wainwright Buy
Mar-09-21 Downgrade Raymond James Strong Buy → Outperform
Mar-09-21 Downgrade Stifel Buy → Hold
Dec-16-20 Initiated Mizuho Buy
Nov-16-20 Upgrade Raymond James Outperform → Strong Buy
Aug-25-20 Initiated Raymond James Outperform
Aug-20-20 Initiated Morgan Stanley Overweight
Jul-07-20 Upgrade Stifel Hold → Buy
Apr-16-20 Initiated Jefferies Buy
Mar-31-20 Upgrade Goldman Neutral → Buy
Mar-06-20 Initiated Citigroup Buy
Dec-16-19 Initiated Guggenheim Buy
Oct-24-19 Initiated Oppenheimer Perform
Oct-01-19 Initiated RBC Capital Mkts Outperform
Sep-13-19 Upgrade SVB Leerink Mkt Perform → Outperform
Sep-10-19 Upgrade Canaccord Genuity Hold → Buy
Jul-23-19 Reiterated Needham Buy
Dec-10-18 Initiated Canaccord Genuity Hold
Sep-21-18 Upgrade Piper Jaffray Neutral → Overweight
Aug-09-18 Reiterated Stifel Hold
Aug-07-18 Initiated Stifel Hold
Aug-06-18 Downgrade Piper Jaffray Overweight → Neutral
Oct-06-17 Resumed Goldman Neutral
View All

Acadia Pharmaceuticals Inc Stock (ACAD) Latest News

pulisher
01:00 AM

Parkinson’s Disease Therapeutic Domain Projected to See Transformational Growth Across the 7MM During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

01:00 AM
pulisher
Apr 21, 2025

Acadia Pharmaceuticals (ACAD) Price Target Lowered by BofA Before Q1 Earnings | ACAD Stock News - GuruFocus

Apr 21, 2025
pulisher
Apr 17, 2025

BofA Adjusts Price Target on ACADIA Pharmaceuticals to $18 From $19, Keeps Neutral Rating - marketscreener.com

Apr 17, 2025
pulisher
Apr 15, 2025

Schizophrenia Market to Reach New Heights in Growth by 2034, - openPR.com

Apr 15, 2025
pulisher
Apr 13, 2025

Declining Stock and Solid Fundamentals: Is The Market Wrong About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? - Yahoo Finance

Apr 13, 2025
pulisher
Apr 12, 2025

Lobbying Update: $20,000 of ACADIA PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative

Apr 12, 2025
pulisher
Apr 11, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Li - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ACAD Stock News - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Apr 11, 2025
pulisher
Apr 11, 2025

Neuroscience Leader Acadia Expands Team with Major Equity Compensation Package - Stock Titan

Apr 11, 2025
pulisher
Apr 09, 2025

Acadia Pharmaceuticals principal accounting officer sells $15,234 in stock By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Acadia Pharmaceuticals principal accounting officer sells $15,234 in stock - Investing.com Australia

Apr 09, 2025
pulisher
Apr 08, 2025

Acadia Pharmaceuticals CFO sells $40,132 in stock - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Acadia Pharmaceuticals CFO sells $40,132 in stock By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

ACADIA Pharmaceuticals Executives Sell Shares to Cover Taxes - TradingView

Apr 08, 2025
pulisher
Apr 08, 2025

Is Weakness In ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - simplywall.st

Apr 08, 2025
pulisher
Mar 31, 2025

DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire

Mar 31, 2025
pulisher
Mar 31, 2025

ACADIA Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily

Mar 31, 2025
pulisher
Mar 28, 2025

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 27, 2025

Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR - Fierce Pharma

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno jumps as analysts say US nod for rare disease drug transforms treatment options - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Acadia Pharmaceuticals principal accounting officer sells $18k in stock By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 26, 2025

Acadia Pharmaceuticals CFO sells $54,065 in stock By Investing.com - Investing.com Canada

Mar 26, 2025
pulisher
Mar 26, 2025

Acadia Pharmaceuticals CFO sells $54,065 in stock - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Acadia Pharmaceuticals principal accounting officer sells $18k in stock - Investing.com

Mar 26, 2025
pulisher
Mar 25, 2025

Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey

Mar 25, 2025
pulisher
Mar 25, 2025

Psychosis in Parkinson's and Alzheimer's Disease Market: - openPR

Mar 25, 2025
pulisher
Mar 24, 2025

Parkinson's Disease Psychosis Treatment Market Size in 7MM - openPR

Mar 24, 2025
pulisher
Mar 20, 2025

Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis - Business Wire

Mar 20, 2025
pulisher
Mar 18, 2025

Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome - Business Wire

Mar 18, 2025
pulisher
Mar 17, 2025

Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now? - Insider Monkey

Mar 17, 2025
pulisher
Mar 17, 2025

ACADIA Pharmaceuticals Earns RS Rating Upgrade - Investor's Business Daily

Mar 17, 2025
pulisher
Mar 16, 2025

Former San Diego Pharma VP pleads guilty to securities fraud for insider trading - MSN

Mar 16, 2025
pulisher
Mar 16, 2025

Ryan Reynolds Announces More to Parkinson’s® Campaign - Business Wire

Mar 16, 2025
pulisher
Mar 14, 2025

Acadia Pharmaceuticals issues new employee stock awards By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Acadia Pharmaceuticals issues new employee stock awards - Investing.com India

Mar 14, 2025
pulisher
Mar 13, 2025

Acadia Sets Stage for Strategic Updates at 3 Major CNS ConferencesKey Dates for Investors - StockTitan

Mar 13, 2025
pulisher
Mar 12, 2025

ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Proficio Capital Partners LLC Invests $272,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Parkinson's Disease Therapeutics Market is expected to reach - openPR

Mar 12, 2025
pulisher
Mar 11, 2025

ACADIA Pharmaceuticals Q4 Earnings: EPS Soars to $0.86, Beating Estimates, While Revenue Misses at $259.6 Million - GuruFocus.com

Mar 11, 2025
pulisher
Mar 10, 2025

Calif. Pharma Exec Pleads Guilty To Insider Trading - Law360

Mar 10, 2025
pulisher
Mar 10, 2025

SEC Sues Former Acadia Pharmaceuticals VP Over Insider Trading - Bloomberg Law News

Mar 10, 2025

Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$19.80
price down icon 1.75%
$70.30
price up icon 2.22%
$32.51
price up icon 0.87%
$26.24
price up icon 1.84%
$102.53
price down icon 0.01%
biotechnology ONC
$248.35
price up icon 8.46%
Cap:     |  Volume (24h):